France: survodutide, and what it actually costs here
Confession thread, sort of.
I went from 1.0mg to 15mg much faster than I should have because the scale had stalled and I got impatient. The stall broke about 14 weeks later, at which point I had no way of knowing whether the dose increase did anything or whether it would have broken anyway.
So now I have constipation I did not need and a data point I cannot interpret. Two lessons in one.
Posting it in the hope that somebody at week 86 reads it before doing the same thing.
best — the order this archive was captured in
hepatic fat and survodutide are the story
the safety profile is not just tirzepatide amplified
hepatic fat and survodutide are the story
glucagon injection is a different vector than GLP-1
Small correction: the trial was 21 weeks, not 10. Does not change your point but people will quote it.
Hepatic fat or MASH or what?
phase 24 data is interesting, phase 32 will be different
This is the "correlation is mechanism" thing again. You changed three variables at once.
glucagon injection is a different vector than GLP-1
I am going to push back on this slightly.
Yeah, glucagon co-agonism is genuinely different.
Maintenance for 8 months now. Weight moves within about 3kg and the dose is a quarter of what it peaked at.
Flair changed to match the content. Read the sidebar before posting next time and we are square.
This is the "correlation is mechanism" thing again. You changed three variables at once.
do not generalise from tirzepatide
phase 6 data is interesting, phase 18 will be different
the GLP-1/glucagon dual is hepatic fat, different from GIP/GLP-1
That is net peptide content, not purity. Different number, different meaning.
glucagon injection is a different vector than GLP-1
glucagon injection is a different vector than GLP-1
Yes, exactly this, and it is the bit that took me 3 weeks to accept.
the GLP-1/glucagon dual is glucagon, different from GIP/GLP-1
the MASH indication changes the risk calculus
Slight fix: the number was 98.7, not 98.3. Decimal point, but a fairly consequential one.
Hepatic fat or MASH or what?
the MASH indication changes the risk calculus
Mechanistically the bit that matters is glucagon. It explains most of the early profile and a decent chunk of the outcome.
do not generalise from tirzepatide
The confident tone is doing a lot of work that the evidence is not.
the heart rate signal is real in the data
- 1hepatic fat and survodutide are the story10 comments in this branch · started by u/old_account_2023
- 2This is the "correlation is mechanism" thing again. You changed three…5 comments in this branch · started by u/throwaway_wl2026